spacer
spacer
Go to PDB code: 
protein ligands links
Transferase PDB id
1xjd
Jmol
Contents
Protein chain
282 a.a. *
Ligands
STU
Waters ×115
* Residue conservation analysis
PDB id:
1xjd
Name: Transferase
Title: Crystal structure of pkc-theta complexed with staurosporine at 2a resolution
Structure: Protein kinasE C, theta type. Chain: a. Fragment: residues 362-706: includes protein kinase domain (residues 380-634). Synonym: pkc-theta, npkc-theta. Engineered: yes
Source: Homo sapiens. Human. Organism_taxid: 9606. Gene: pkc. Expressed in: escherichia coli bl21(de3). Expression_system_taxid: 469008. Other_details: the sequence of this peptide can be found naturally in homo sapiens (human).
Resolution:
2.00Å     R-factor:   0.201     R-free:   0.216
Authors: Z.B.Xu
Key ref:
Z.B.Xu et al. (2004). Catalytic domain crystal structure of protein kinase C-theta (PKCtheta). J Biol Chem, 279, 50401-50409. PubMed id: 15364937 DOI: 10.1074/jbc.M409216200
Date:
23-Sep-04     Release date:   19-Oct-04    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
Pfam   ArchSchema ?
Q04759  (KPCT_HUMAN) -  Protein kinase C theta type
Seq:
Struc:
 
Seq:
Struc:
706 a.a.
282 a.a.*
Key:    PfamA domain  Secondary structure  CATH domain
* PDB and UniProt seqs differ at 9 residue positions (black crosses)

 Enzyme reactions 
   Enzyme class: E.C.2.7.11.13  - Protein kinase C.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: ATP + a protein = ADP + a phosphoprotein
ATP
+ protein
= ADP
+ phosphoprotein
Molecule diagrams generated from .mol files obtained from the KEGG ftp site
 Gene Ontology (GO) functional annotation 
  GO annot!
  Biological process     protein amino acid phosphorylation   1 term 
  Biochemical function     protein kinase activity     3 terms  

 

 
    reference    
 
 
DOI no: 10.1074/jbc.M409216200 J Biol Chem 279:50401-50409 (2004)
PubMed id: 15364937  
 
 
Catalytic domain crystal structure of protein kinase C-theta (PKCtheta).
Z.B.Xu, D.Chaudhary, S.Olland, S.Wolfrom, R.Czerwinski, K.Malakian, L.Lin, M.L.Stahl, D.Joseph-McCarthy, C.Benander, L.Fitz, R.Greco, W.S.Somers, L.Mosyak.
 
  ABSTRACT  
 
A member of the novel protein kinase C (PKC) subfamily, PKC, is an essential component of the T cell synapse and is required for optimal T cell activation and interleukin-2 production. Selective involvement of PKC in TCR signaling makes this enzyme an attractive therapeutic target in T cell-mediated disease processes. In this report we describe the crystal structure of the catalytic domain of PKC at 2.0-A resolution. Human recombinant PKC kinase domain was expressed in bacteria as catalytically active phosphorylated enzyme and co-crystallized with its subnanomolar, ATP site inhibitor staurosporine. The structure follows the classic bilobal kinase fold and shows the enzyme in its active conformation and phosphorylated state. Inhibitory interactions between conserved features of staurosporine and the ATP-binding cleft are accompanied by closing of the glycine-rich loop, which also maintains an inhibitory arrangement by blocking the phosphate recognition subsite. The two major phosphorylation sites, Thr-538 in the activation loop and Ser-695 in the hydrophobic motif, are both occupied in the structure, playing key roles in stabilizing active conformation of the enzyme and indicative of PKC autocatalytic phosphorylation and activation during bacterial expression. The PKC-staurosporine complex represents the first kinase domain crystal structure of any PKC isotypes to be determined and as such should provide valuable insight into PKC specificity and into rational drug design strategies for PKC selective leads.
 
  Selected figure(s)  
 
Figure 2.
FIG. 2. Overall structure of the PKC -staurosporine complex and comparison with the structure of the PKA-staurosporine-PKI complex. A, ribbon representation of the PKC kinase domain structure. The N-lobe is cyan and the C-lobe is blue. The glycine-rich loop, activation loop, and HM segment are highlighted in red. Staurosporine and phosphorylated residues are shown in stick representation. B, superposition of PKC -staurosporine (color coding is the same as described for A) and PKA-staurosporine-PKI structures (yellow ribbons and sticks; PDB code: 1STC [PDB] (20)). Phosphorylated sites in PKA are also shown. Structures were aligned using the central helices from the C-lobe. Both staurosporine-bound kinases display intermediate lobe structures with conformational differences in the glycine-rich loop.
Figure 4.
FIG. 4. The activation loop and helix C. The ribbon drawing of PKC (N-lobe in cyan, C-lobe in blue) highlights key structural motifs at the catalytic cleft. Selected residues are in stick representation. Dashed red lines depict specific hydrogen-bonding interactions of the essential Thr-538(P) phosphate with cationic pocket (Arg-503, Lys-527) and of the C helix with catalytic Lys-409 and activation loop (Glu-528).
 
  The above figures are reprinted by permission from the ASBMB: J Biol Chem (2004, 279, 50401-50409) copyright 2004.  
  Figures were selected by the author.  

Literature references that cite this PDB file's key reference

  PubMed id Reference
21435888 J.F.Djung, R.J.Mears, C.A.Montalbetti, T.S.Coulter, A.Golebiowski, A.N.Carr, O.Barker, K.D.Greis, S.Zhou, E.Dolan, and G.F.Davis (2011).
The synthesis and evaluation of indolylureas as PKCα inhibitors.
  Bioorg Med Chem, 19, 2742-2750.  
21215369 T.A.Leonard, B.Różycki, L.F.Saidi, G.Hummer, and J.H.Hurley (2011).
Crystal structure and allosteric activation of protein kinase C βII.
  Cell, 144, 55-66.
PDB code: 3pfq
19934406 A.C.Newton (2010).
Protein kinase C: poised to signal.
  Am J Physiol Endocrinol Metab, 298, E395-E402.  
19603203 C.E.Cassidy, and W.N.Setzer (2010).
Cancer-relevant biochemical targets of cytotoxic Lonchocarpus flavonoids: a molecular docking analysis.
  J Mol Model, 16, 311-326.  
20237675 J.van Ameijde, A.J.Poot, L.T.van Wandelen, A.E.Wammes, R.Ruijtenbeek, D.T.Rijkers, and R.M.Liskamp (2010).
Preparation of novel alkylated arginine derivatives suitable for click-cycloaddition chemistry and their incorporation into pseudosubstrate- and bisubstrate-based kinase inhibitors.
  Org Biomol Chem, 8, 1629-1639.  
20445233 T.Takimura, K.Kamata, K.Fukasawa, H.Ohsawa, H.Komatani, T.Yoshizumi, I.Takahashi, H.Kotani, and Y.Iwasawa (2010).
Structures of the PKC-iota kinase domain in its ATP-bound and apo forms reveal defined structures of residues 533-551 in the C-terminal tail and their roles in ATP binding.
  Acta Crystallogr D Biol Crystallogr, 66, 577-583.
PDB codes: 3a8w 3a8x
19765263 A.Filatova, M.Leyerer, V.Gorboulev, C.Chintalapati, Y.Reinders, T.D.Müller, A.Srinivasan, S.Hübner, and H.Koepsell (2009).
Novel shuttling domain in a regulator (RSC1A1) of transporter SGLT1 steers cell cycle-dependent nuclear location.
  Traffic, 10, 1599-1618.  
19465915 A.J.Cameron, C.Escribano, A.T.Saurin, B.Kostelecky, and P.J.Parker (2009).
PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity.
  Nat Struct Mol Biol, 16, 624-630.  
19618415 A.J.Poot, J.van Ameijde, M.Slijper, A.van den Berg, R.Hilhorst, R.Ruijtenbeek, D.T.Rijkers, and R.M.Liskamp (2009).
Development of selective bisubstrate-based inhibitors against protein kinase C (PKC) isozymes by using dynamic peptide microarrays.
  Chembiochem, 10, 2042-2051.  
19164598 B.Nagy, K.Bhavaraju, T.Getz, Y.S.Bynagari, S.Kim, and S.P.Kunapuli (2009).
Impaired activation of platelets lacking protein kinase C-theta isoform.
  Blood, 113, 2557-2567.  
19364770 C.C.Huang, K.Yoshino-Koh, and J.J.Tesmer (2009).
A surface of the kinase domain critical for the allosteric activation of G protein-coupled receptor kinases.
  J Biol Chem, 284, 17206-17215.  
19152005 J.H.Daniel (2009).
A fitness-based interferential genetics approach using hypertoxic/inactive gene alleles as references.
  Mol Genet Genomics, 281, 437-445.  
19309729 J.M.Elkins, A.Amos, F.H.Niesen, A.C.Pike, O.Fedorov, and S.Knapp (2009).
Structure of dystrophia myotonica protein kinase.
  Protein Sci, 18, 782-791.
PDB code: 2vd5
  18923184 S.F.Steinberg (2008).
Structural basis of protein kinase C isoform function.
  Physiol Rev, 88, 1341-1378.  
18214957 S.Tang, V.Xiao, L.Wei, C.I.Whiteside, and L.P.Kotra (2008).
Protein kinase C isozymes and their selectivity towards ruboxistaurin.
  Proteins, 72, 447-460.  
18508761 Y.Liu, K.S.Matthews, and S.E.Bondos (2008).
Multiple intrinsically disordered sequences alter DNA binding by the homeodomain of the Drosophila hox protein ultrabithorax.
  J Biol Chem, 283, 20874-20887.  
17500509 H.Al-Ali, T.J.Ragan, X.Gao, and T.K.Harris (2007).
Reconstitution of modular PDK1 functions on trans-splicing of the regulatory PH and catalytic kinase domains.
  Bioconjug Chem, 18, 1294-1302.  
17217965 P.C.Whitford, O.Miyashita, Y.Levy, and J.N.Onuchic (2007).
Conformational transitions of adenylate kinase: switching by cracking.
  J Mol Biol, 366, 1661-1671.  
17335005 S.Ranganathan, Y.Wang, F.G.Kern, Z.Qu, and R.Li (2007).
Activation loop phosphorylation-independent kinase activity of human protein kinase C zeta.
  Proteins, 67, 709-719.  
17914234 V.S.Gowri, K.Anamika, S.Gore, and N.Srinivasan (2007).
Analysis on sliding helices and strands in protein structural comparisons: a case study with protein kinases.
  J Biosci, 32, 921-928.  
16445370 C.A.O'Brian, F.Chu, W.G.Bornmann, and D.S.Maxwell (2006).
Protein kinase Calpha and epsilon small-molecule targeted therapeutics: a new roadmap to two Holy Grails in drug discovery?
  Expert Rev Anticancer Ther, 6, 175-186.  
17119643 C.Sánchez, C.Méndez, and J.A.Salas (2006).
Indolocarbazole natural products: occurrence, biosynthesis, and biological activity.
  Nat Prod Rep, 23, 1007-1045.  
17110931 M.Engel, V.Hindie, L.A.Lopez-Garcia, A.Stroba, F.Schaeffer, I.Adrian, J.Imig, L.Idrissova, W.Nastainczyk, S.Zeuzem, P.M.Alzari, R.W.Hartmann, A.Piiper, and R.M.Biondi (2006).
Allosteric activation of the protein kinase PDK1 with low molecular weight compounds.
  EMBO J, 25, 5469-5480.  
17084073 M.G.Gold, D.Barford, and D.Komander (2006).
Lining the pockets of kinases and phosphatases.
  Curr Opin Struct Biol, 16, 693-701.  
16762554 M.Tanaka, S.Sagawa, J.Hoshi, F.Shimoma, K.Yasue, M.Ubukata, T.Ikemoto, Y.Hase, M.Takahashi, T.Sasase, N.Ueda, M.Matsushita, and T.Inaba (2006).
Synthesis, SAR studies, and pharmacological evaluation of 3-anilino-4-(3-indolyl) maleimides with conformationally restricted structure as orally bioavailable PKCbeta-selective inhibitors.
  Bioorg Med Chem, 14, 5781-5794.  
16785988 S.Ohashi, G.Sakashita, R.Ban, M.Nagasawa, H.Matsuzaki, Y.Murata, H.Taniguchi, H.Shima, K.Furukawa, and T.Urano (2006).
Phospho-regulation of human protein kinase Aurora-A: analysis using anti-phospho-Thr288 monoclonal antibodies.
  Oncogene, 25, 7691-7702.  
16792700 S.Sánchez-Bautista, A.Kazaks, M.Beaulande, A.Torrecillas, S.Corbalán-García, and J.C.Gómez-Fernández (2006).
Structural study of the catalytic domain of PKCzeta using infrared spectroscopy and two-dimensional infrared correlation spectroscopy.
  FEBS J, 273, 3273-3286.  
16288296 C.C.Kumar, and V.Madison (2005).
AKT crystal structure and AKT-specific inhibitors.
  Oncogene, 24, 7493-7501.  
16252004 N.Thuille, I.Heit, F.Fresser, N.Krumböck, B.Bauer, S.Leuthaeusser, S.Dammeier, C.Graham, T.D.Copeland, S.Shaw, and G.Baier (2005).
Critical role of novel Thr-219 autophosphorylation for the cellular function of PKCtheta in T lymphocytes.
  EMBO J, 24, 3869-3880.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time. Where a reference describes a PDB structure, the PDB code is shown on the right.